WO2001051633A3 - Compositions and methods for the therapy and diagnosis of prostate cancer - Google Patents

Compositions and methods for the therapy and diagnosis of prostate cancer Download PDF

Info

Publication number
WO2001051633A3
WO2001051633A3 PCT/US2001/001574 US0101574W WO0151633A3 WO 2001051633 A3 WO2001051633 A3 WO 2001051633A3 US 0101574 W US0101574 W US 0101574W WO 0151633 A3 WO0151633 A3 WO 0151633A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
prostate cancer
therapy
methods
Prior art date
Application number
PCT/US2001/001574
Other languages
French (fr)
Other versions
WO2001051633A2 (en
WO2001051633A9 (en
Inventor
Jiangchun Xu
Davin C Dillon
Jennifer L Mitcham
Susan L Harlocker
Yuqiu Jiang
Steven G Reed
Michael D Kalos
Gary Richard Fanger
Craig H Day
Marc W Retter
John A Stolk
Yasir A W Skeiky
Aijun Wang
Madeleine Joy Meagher
Original Assignee
Corixa Corp
Jiangchun Xu
Davin C Dillon
Jennifer L Mitcham
Susan L Harlocker
Yuqiu Jiang
Steven G Reed
Michael D Kalos
Gary Richard Fanger
Craig H Day
Marc W Retter
John A Stolk
Yasir A W Skeiky
Aijun Wang
Madeleine Joy Meagher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0203968A priority Critical patent/HUP0203968A3/en
Priority to BR0107643-4A priority patent/BR0107643A/en
Priority to MXPA02006934A priority patent/MXPA02006934A/en
Priority to AU34474/01A priority patent/AU3447401A/en
Priority to CA002397741A priority patent/CA2397741A1/en
Priority to EP01906582A priority patent/EP1261708A2/en
Application filed by Corixa Corp, Jiangchun Xu, Davin C Dillon, Jennifer L Mitcham, Susan L Harlocker, Yuqiu Jiang, Steven G Reed, Michael D Kalos, Gary Richard Fanger, Craig H Day, Marc W Retter, John A Stolk, Yasir A W Skeiky, Aijun Wang, Madeleine Joy Meagher filed Critical Corixa Corp
Priority to IL15073201A priority patent/IL150732A0/en
Priority to JP2001551207A priority patent/JP2003528591A/en
Publication of WO2001051633A2 publication Critical patent/WO2001051633A2/en
Publication of WO2001051633A3 publication Critical patent/WO2001051633A3/en
Priority to NO20023402A priority patent/NO20023402L/en
Publication of WO2001051633A9 publication Critical patent/WO2001051633A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.
PCT/US2001/001574 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer WO2001051633A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR0107643-4A BR0107643A (en) 2000-01-14 2001-01-16 Compositions and processes for prostate cancer therapy and diagnosis
MXPA02006934A MXPA02006934A (en) 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer.
AU34474/01A AU3447401A (en) 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer
CA002397741A CA2397741A1 (en) 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer
EP01906582A EP1261708A2 (en) 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer
HU0203968A HUP0203968A3 (en) 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer
IL15073201A IL150732A0 (en) 2000-01-14 2001-01-16 Prostate specific polypeptides, polynucleotides that encode said polypeptides and pharmaceutical compositions containing the same
JP2001551207A JP2003528591A (en) 2000-01-14 2001-01-16 Compositions and methods for treatment and diagnosis of prostate cancer
NO20023402A NO20023402L (en) 2000-01-14 2002-07-15 Mixtures and Methods for the Treatment and Diagnosis of Prostate Cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48367200A 2000-01-14 2000-01-14
US09/483,672 2000-01-14

Publications (3)

Publication Number Publication Date
WO2001051633A2 WO2001051633A2 (en) 2001-07-19
WO2001051633A3 true WO2001051633A3 (en) 2002-06-20
WO2001051633A9 WO2001051633A9 (en) 2002-10-31

Family

ID=23921037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001574 WO2001051633A2 (en) 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer

Country Status (16)

Country Link
EP (1) EP1261708A2 (en)
JP (1) JP2003528591A (en)
KR (1) KR20030016217A (en)
CN (1) CN1436234A (en)
AU (1) AU3447401A (en)
BR (1) BR0107643A (en)
CA (1) CA2397741A1 (en)
CZ (1) CZ20022756A3 (en)
HU (1) HUP0203968A3 (en)
IL (1) IL150732A0 (en)
MX (1) MXPA02006934A (en)
NO (1) NO20023402L (en)
PL (1) PL356908A1 (en)
RU (1) RU2002121771A (en)
WO (1) WO2001051633A2 (en)
ZA (1) ZA200206400B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096907B2 (en) 2004-12-24 2015-08-04 Stichting Katholieke Universiteit, The University Medical Centre Nijmegen Prostate cancer prognostic compositions and kits

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
EP1007650B1 (en) 1997-04-10 2009-03-18 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, pca3 genes, and methods of use
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP2080802B1 (en) 1998-06-01 2017-03-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US7022497B1 (en) 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
DK1222266T3 (en) 1999-09-29 2006-07-10 Diagnocure Inc PCA3 messenger RNA in benign and malignant prostate tissue
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
ES2282142T3 (en) * 1999-10-07 2007-10-16 Corixa Corporation A SEQUENCE OF MICOBACTERIUM TUBERCULOSIS FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS.
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
CA2403909A1 (en) * 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ES2333579T3 (en) 2000-06-20 2010-02-24 Corixa Corporation FUSION PROTEINS OF MYCOBACTERIUM TUBERCULOSIS.
AU2001281322A1 (en) * 2000-07-13 2002-01-30 Biogen, Inc. Methods of identifying renal protective factors
US7205108B2 (en) 2000-07-28 2007-04-17 Ulrich Wissenbach Trp8, Trp9 and Trp10, novel markers for cancer
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
JP2005504513A (en) * 2001-05-09 2005-02-17 コリクサ コーポレイション Compositions and methods for treatment and diagnosis of prostate cancer
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR100576674B1 (en) * 2001-06-20 2006-05-10 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JP2005505271A (en) * 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド Nucleic acids and corresponding proteins given the name STEAP-1 useful in the treatment and detection of cancer
EP1474516B1 (en) 2002-01-25 2013-03-27 The Regents of The University of California Methods of modulating cold sensory perception
DE10215321A1 (en) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh New nucleic acid encoding Trpp8 splice variants, useful for diagnosis of prostatic cancer, and to screen for diagnostic or therapeutic agents, also related proteins
CN100360558C (en) * 2002-06-11 2008-01-09 葛兰素史密丝克莱恩生物有限公司 Immunogenic compositions
DE10234901A1 (en) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh New nucleic acids encoding Mrp4, useful in the diagnosis of prostatic, bladder and ovarian tumors, also in screening for specific binding agents, and potential therapeutic agents
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
JP4824540B2 (en) 2003-02-07 2011-11-30 ダイアノキュアー インク． How to detect prostate cancer in a sample
DK1742966T3 (en) 2004-04-22 2014-02-03 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2612168A1 (en) * 2005-06-14 2006-12-21 Dnavec Corporation Methods for producing antibodies
ES2535637T3 (en) 2006-10-27 2015-05-13 Genentech, Inc. Antibodies and immunoconjugates and uses for them
PL2855667T3 (en) * 2012-05-25 2024-03-25 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
CN104357451B (en) * 2014-12-02 2016-09-21 广州市番禺区中心医院 For the siRNA of DD3 gene and expression vector establishment thereof and application
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520566D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
DK3558339T3 (en) * 2016-12-22 2024-02-26 Cue Biopharma Inc T-cell modulating multimeric polypeptides and methods of use thereof
CN110494452B (en) 2017-04-03 2023-08-25 豪夫迈·罗氏有限公司 Antibodies that bind STEAP-1
CN110988348B (en) * 2019-11-06 2022-07-05 北京九强生物技术股份有限公司 Free prostate specific antigen detection kit and preparation method thereof
CN114250238B (en) * 2021-11-26 2023-08-25 北京航空航天大学 Gene-encoded neuron development regulatory polypeptide and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033909A2 (en) * 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO1998037418A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
WO1998037093A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001034802A2 (en) * 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033909A2 (en) * 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO1998037418A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
WO1998037093A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001034802A2 (en) * 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SJOGREN H O: "Therapeutic immunization against cancer antigens using genetically engineered cells", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 3, no. 3, 1 October 1997 (1997-10-01), pages 161 - 172, XP004097000, ISSN: 1380-2933 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096907B2 (en) 2004-12-24 2015-08-04 Stichting Katholieke Universiteit, The University Medical Centre Nijmegen Prostate cancer prognostic compositions and kits

Also Published As

Publication number Publication date
CA2397741A1 (en) 2001-07-19
NO20023402D0 (en) 2002-07-15
RU2002121771A (en) 2004-03-10
MXPA02006934A (en) 2003-01-28
CN1436234A (en) 2003-08-13
AU3447401A (en) 2001-07-24
NO20023402L (en) 2002-08-29
KR20030016217A (en) 2003-02-26
HUP0203968A3 (en) 2004-09-28
ZA200206400B (en) 2004-01-21
IL150732A0 (en) 2003-02-12
BR0107643A (en) 2003-06-10
WO2001051633A2 (en) 2001-07-19
CZ20022756A3 (en) 2003-02-12
WO2001051633A9 (en) 2002-10-31
EP1261708A2 (en) 2002-12-04
PL356908A1 (en) 2004-07-12
JP2003528591A (en) 2003-09-30
HUP0203968A2 (en) 2003-03-28

Similar Documents

Publication Publication Date Title
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002014503A3 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002012328A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002016413A3 (en) Cripto tumour polypeptide
WO2002058534A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
WO2003086175A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 150732

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 551207

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027009144

Country of ref document: KR

Ref document number: 2397741

Country of ref document: CA

Ref document number: PA/a/2002/006934

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 520395

Country of ref document: NZ

Ref document number: 34474/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01042/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002/06400

Country of ref document: ZA

Ref document number: 200206400

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PV2002-2756

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2002 2002121771

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001906582

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018065260

Country of ref document: CN

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2001906582

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-2756

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020027009144

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2002-2756

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001906582

Country of ref document: EP